Asset profile
VentriGel
Biologic — subtype unspecified
Evidence outlook · lead readout
NCT02305602 · Myocardial Infarction, Heart Failure, Left Ventricular Remodeling
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT02305602: Every one of the 15 participants received VentriGel with no comparison group, no randomization and no blinding, so the study cannot show whether any outcome was actually caused by the treatment. Its primary aim was to monitor for serious side effects, and no results have been posted yet.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.